The Drug Enforcement Administration today its proposed 2019 aggregate production quotas for certain controlled substances, which the agency would reduce manufacturing quotas for six frequently misused opioids by an average 10 percent. The proposed rule will be published in the Aug. 20 Federal Register with comments accepted for 30 days. AHA and others have urged DEA to include drug shortages as a factor when setting and adjusting aggregate and individual manufacturers’ production quotas for controlled substances.
 

Related News Articles

Headline
The Government Accountability Office yesterday released a report calling for the Department of Health and Human Services to improve its efforts responding to…
Headline
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class non-opioid drug, to treat moderate to…
Headline
In this conversation, Vinnidhy Dave, D.O., hospice specialist and director of palliative medicine at Englewood Health Physician Network, and Lauren Savage,…
Headline
In this conversation, Matthew Hoag, director of integrated behavioral health at Denver Health, shares how the organization is innovating through integration to…
Headline
The AHA June 7 submitted comments on a discussion draft of the Drug Shortage Prevention and Mitigation Act, bipartisan legislation proposing to provide…
Blog
The inability of many patients to obtain needed drug therapies due to either high prices or shortages has negatively affected patient outcomes.1 Nearly 30% of…